News

Shattuck Labs Secures $103 Million for Clinical Development

Shattuck Labs Secures $103 Million for Clinical Development

Shattuck Labs Secures Oversubscribed Financing

Shattuck Labs, Inc. (NASDAQ: STTK), known for its innovative therapeutic approaches targeting autoimmune diseases, has successfully completed a private placement financing, bringing in up to approximately $103 million in gross proceeds. This significant funding is anticipated to propel the clinical development of their promising product candidate, SL-325, through multiple Phase 2 clinical trials.

Overview of Private Placement

The financing was led by OrbiMed with an impressive involvement from various investors, which included both new patrons and existing stakeholders. The deal involves the sale of 15,225,158 shares of common stock and the issuance of pre-funded warrants allowing investors to purchase an additional 37,410,188 shares. These financial instruments come at a price of $0.8677 per share, with accompanying warrants that have an exercise price of $1.0846.

Strategic Use of Proceeds

Shattuck Labs is poised to utilize the proceeds from this financing to streamline the development of SL-325, a potentially groundbreaking DR3 blocking antibody aimed at treating conditions like inflammatory bowel disease (IBD). The firm projects that these funds will also support another autoimmune disease project, SL-425, ensuring a diversified development pathway.

Clinical Trials and Projections

Starting this quarter, enrollment for the Phase 1 clinical trial for SL-325 is expected to begin, pending regulatory approvals. Excitingly, data from these trials will ultimately guide the company's strategy as they transition into critical Phase 2 trials. The funding will allow Shattuck to fully assess whether SL-325 can outperform existing treatments, primarily by blocking the DR3 pathway effectively.

The Commitment to Innovation

The proceeds from the private placement, expected to total about $46 million initially—with the potential for an extra $57 million if the attached warrants get exercised—will equip Shattuck Labs to maintain operational capacity through at least 2029. CEO Taylor Schreiber emphasized that this infusion of capital is essential to advance their pipeline efficiently and maintain focus on their strategic research objectives.

The Significance of SL-325

SL-325 stands as a pivotal candidate within Shattuck Labs' arsenal against autoimmune diseases. This antibody may represent the first of its kind developed to target the Death Receptor 3 (DR3), aiming for a robust blockade of the DR3/TL1A signaling pathway, which preliminary studies indicate might confer superior efficacy compared to current alternatives. With a Phase 1 trial slated for initiation, Shattuck is optimistic about the clinical implications for patients suffering from Crohn’s disease, ulcerative colitis, and possibly beyond.

Looking Forward

With the robust financial backing and a dedicated approach to drug development, Shattuck Labs is well-positioned to make significant strides in the biopharmaceutical landscape. The commitment to innovation and clinical excellence will allow the company to monitor and adapt its strategies as new data from their trials becomes available.

About Shattuck Labs, Inc.

Shattuck Labs, Inc. is a biotechnology company at the forefront of developing pioneering therapies for inflammatory and autoimmune diseases. Their focus lies on leveraging advanced engineering and therapeutic strategies to cultivate unique treatment paradigms, starting with SL-325, an innovative DR3 antagonist antibody. With operational facilities located in Austin, Texas, and Durham, North Carolina, Shattuck Labs is committed to advancing high-impact health solutions for patients worldwide.

Frequently Asked Questions

What is the purpose of the recent private placement?

The private placement aims to fund the clinical development of SL-325 and other pipeline projects, ensuring operational capacity into 2029.

Who led the financing for Shattuck Labs?

The financing was primarily led by OrbiMed, including participation from various new and existing investors.

What conditions are needed for the private placement to close?

The closing of this private placement depends on the clearance of the Investigational New Drug Application (IND) for SL-325 and fulfilling other standard conditions.

What are the expected outcomes of the clinical trials for SL-325?

The trials are expected to reveal whether SL-325 provides better effectiveness and less immunogenicity compared to TL1A blocking antibodies.

How does SL-325 differ from other treatments currently available?

SL-325 is designed to target the DR3 pathway selectively, potentially offering a more complete blockade than existing therapies that target TL1A.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 113

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
TNBC Advocate Campaign Targets Gaps in Patient Clarity

Updated Category News Views 70

Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...

Continue Reading
Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 66

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
J. Harmon Tests a Smarter Cannabis Accessory Niche

Updated Category News Views 118

Aisle Space Is the Real Prize Most cannabis accessory launches arrive dressed up like a gimmick and disappear before anyone has reordered them. J. Harmon has a more sensible target: give women products that look deliberate, work in everyday routines and do not demand designer-level money. The brand is set to debut at MJBizCon 2026 in Las Vegas, with LUVBUDS handling...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 144

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Allstate's October Cat Loss Lands at $232 Million Net

Updated Category News Views 75

October’s weather bill arrived without much poetry: $232 million in estimated catastrophe losses at Allstate. Reported on November 19, that figure falls to $184 million after tax, and it deserves a clear-eyed read rather than the usual insurance-stock theatrics. A single monthly catastrophe tally is not a verdict on the company, but it is absolutely part of the...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 105

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 36

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 79

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 106

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading

Top 5 Most Recently Viewed Articles

Spectral Medical Secures $3 Million Funding for Growth

Updated Category News Views 100

Spectral Medical Secures a $3 Million Funding Boost In a significant development, Spectral Medical Inc. has successfully secured a $3 million advance through a collaboration with Vantive US Healthcare LLC. This funding serves as a vital resource for Spectral, a company dedicated to enhancing therapeutic treatments for sepsis and septic shock. Strengthening Financial...

Continue Reading
Exploring the Thriving Hyperscale Data Center Industry

Updated Category News Views 192

Hyperscale Data Centers: A Market on the Move The global hyperscale data center market is set to expand quickly, with projections pointing to USD 177.58 billion in the coming years, up from USD 111.57 billion in the previous year. From 2024 to 2032, forecasts call for a compound annual growth rate (CAGR) of 5.3%. Behind that curve: rising demand for cloud services, rapid...

Continue Reading
Stock Market Sees Positive Gains Amid Mixed Economic Sentiment

Updated Category News Views 122

Stock Market Overview and Performance The Fear and Greed index indicates stability in market perceptions, remaining in the "Neutral" zone despite fluctuations. On the latest trading day, U.S. stocks demonstrated an upward trend, specifically highlighting a surge of over 300 points in the Dow Jones index during this session. Key Stock Performances Particularly notable were...

Continue Reading
Peyto Exploration Declares Monthly Dividend for November 2025

Updated Category News Views 161

Peyto Exploration & Development Corp. Announces Dividend Details CALGARY, Alberta — Peyto Exploration & Development Corp. (TSX: PEY) proudly announces that its monthly dividend of $0.11 per common share will be disbursed on November 14, 2025. This payment is dedicated to shareholders who are on record as of October 31, 2025. Understanding the Dividend Payment The...

Continue Reading
Investors Alert: Rentokil Initial Class Action Lawsuit Details

Updated Category News Views 333

Rentokil Initial Class Action Lawsuit Overview In a recent development, investors holding American Depositary Shares (ADSs) in Rentokil Initial plc are being notified of an impending deadline in a securities class action lawsuit. Those who have suffered losses exceeding $100,000 can apply to be lead plaintiffs. The deadline for filing these applications is January 27,...

Continue Reading